Literature DB >> 28151490

Efficacy of early treatment in patients with cobalamin C disease identified by newborn screening: a 16-year experience.

Rebecca C Ahrens-Nicklas1, Ashley M Whitaker2, Paige Kaplan1, Sanmati Cuddapah1, Jessica Burfield1, Jennifer Blair1, Ligia Brochi1, Marc Yudkoff1, Can Ficicioglu1.   

Abstract

PURPOSE: Despite implementation of newborn screening (NBS), outcomes in cobalamin C disease (cblC) remain poor. Therapy with hydroxycobalamin and betaine is widely used, but dietary recommendations vary among metabolic centers. We present a longitudinal analysis of the relationship between metabolic control, diet, and outcomes in a cohort of cblC patients.
METHODS: We completed a retrospective analysis of 12 patients with cblC referred for abnormal NBS results and followed in our center between 1999 and 2015.
RESULTS: Of the patients, 87.5% had intellectual disability and 75% had retinopathy; 16.7% had one episode of mild acidosis. However, no patients manifested major metabolic decompensation. Developmental outcomes correlated more closely with initial metabolic abnormalities than with long-term metabolic control. Increased intake of medical foods resulted in better control but also perturbations in the ratios of essential amino acids and lower z-scores for head circumference. We found no relationship between diet and cognitive outcomes.
CONCLUSIONS: Although dietary therapy for cblC patients improves metabolic control, few patients experience metabolic decompensation regardless of diet. Increased incomplete protein intake is not correlated with improvements in outcomes. Overall, outcomes are poor despite early initiation of therapy and regardless of the dietary strategy used.Genet Med advance online publication 02 February 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28151490      PMCID: PMC6082364          DOI: 10.1038/gim.2016.214

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  26 in total

Review 1.  Branched-chain amino acids: enzyme and substrate regulation.

Authors:  John T Brosnan; Margaret E Brosnan
Journal:  J Nutr       Date:  2006-01       Impact factor: 4.798

2.  A derangement in B 12 metabolism leading to homocystinemia, cystathioninemia and methylmalonic aciduria.

Authors:  S H Mudd; H L Levy; R H Abeles; J P Jennedy
Journal:  Biochem Biophys Res Commun       Date:  1969-04-10       Impact factor: 3.575

Review 3.  Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management.

Authors:  Nuria Carrillo-Carrasco; Randy J Chandler; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

4.  Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: focus on cerebral amino acid influx.

Authors:  Kevin A Strauss; Joan Brumbaugh; Alana Duffy; Bridget Wardley; Donna Robinson; Christine Hendrickson; Silvia Tortorelli; Ann B Moser; Erik G Puffenberger; Nicholas L Rider; D Holmes Morton
Journal:  Mol Genet Metab       Date:  2011-07-12       Impact factor: 4.797

5.  Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type.

Authors:  Jordan P Lerner-Ellis; Jamie C Tirone; Peter D Pawelek; Carole Doré; Janet L Atkinson; David Watkins; Chantal F Morel; T Mary Fujiwara; Emily Moras; Angela R Hosack; Gail V Dunbar; Hana Antonicka; Vince Forgetta; C Melissa Dobson; Daniel Leclerc; Roy A Gravel; Eric A Shoubridge; James W Coulton; Pierre Lepage; Johanna M Rommens; Kenneth Morgan; David S Rosenblatt
Journal:  Nat Genet       Date:  2005-11-27       Impact factor: 38.330

6.  Prenatal and postnatal treatment in cobalamin C defect.

Authors:  Martina Huemer; Burkhard Simma; Brian Fowler; Terttu Suormala; Olaf A Bodamer; Jörn Oliver Sass
Journal:  J Pediatr       Date:  2005-10       Impact factor: 4.406

7.  Cobalamin C Disease Missed by Newborn Screening in a Patient with Low Carnitine Level.

Authors:  Rebecca C Ahrens-Nicklas; Esra Serdaroglu; Colleen Muraresku; Can Ficicioglu
Journal:  JIMD Rep       Date:  2015-03-13

Review 8.  Cobalamin C defect: natural history, pathophysiology, and treatment.

Authors:  Diego Martinelli; Federica Deodato; Carlo Dionisi-Vici
Journal:  J Inherit Metab Dis       Date:  2010-07-15       Impact factor: 4.982

9.  Potential for misdiagnosis due to lack of metabolic derangement in combined methylmalonic aciduria/hyperhomocysteinemia (cblC) in the neonate.

Authors:  Cary O Harding; De-Ann M Pillers; Robert D Steiner; Teodoro Bottiglieri; David S Rosenblatt; Jason Debley; K Michael Gibson
Journal:  J Perinatol       Date:  2003 Jul-Aug       Impact factor: 2.521

10.  The adolescent and adult form of cobalamin C disease: clinical and molecular spectrum.

Authors:  C Thauvin-Robinet; E Roze; G Couvreur; M-H Horellou; F Sedel; D Grabli; G Bruneteau; C Tonneti; A Masurel-Paulet; D Perennou; T Moreau; M Giroud; H Ogier de Baulny; S Giraudier; L Faivre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-02-01       Impact factor: 10.154

View more
  8 in total

1.  Milder clinical and biochemical phenotypes associated with the c.482G>A (p.Arg161Gln) pathogenic variant in cobalamin C disease: Implications for management and screening.

Authors:  Mohammed Almannai; Ronit Marom; Kristian Divin; Fernando Scaglia; V Reid Sutton; William J Craigen; Brendan Lee; Lindsay C Burrage; Brett H Graham
Journal:  Mol Genet Metab       Date:  2017-06-29       Impact factor: 4.797

Review 2.  Effects of medical food leucine content in the management of methylmalonic and propionic acidemias.

Authors:  Jennifer G Myles; Irini Manoli; Charles P Venditti
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2018-01       Impact factor: 4.294

Review 3.  Treatable Inherited Movement Disorders in Children: Spotlight on Clinical and Biochemical Features.

Authors:  Serena Galosi; Francesca Nardecchia; Vincenzo Leuzzi
Journal:  Mov Disord Clin Pract       Date:  2020-02-04

Review 4.  Versatile enzymology and heterogeneous phenotypes in cobalamin complementation type C disease.

Authors:  Anna J Esser; Srijan Mukherjee; Ilia A Dereven'kov; Sergei V Makarov; Donald W Jacobsen; Ute Spiekerkoetter; Luciana Hannibal
Journal:  iScience       Date:  2022-08-18

5.  The Follow-Up of Chinese Patients in cblC Type Methylmalonic Acidemia Identified Through Expanded Newborn Screening.

Authors:  Shiying Ling; Shengnan Wu; Ruixue Shuai; Yue Yu; Wenjuan Qiu; Haiyan Wei; Chiju Yang; Peng Xu; Hui Zou; Jizhen Feng; Tingting Niu; Haili Hu; Huiwen Zhang; Lili Liang; Deyun Lu; Zhuwen Gong; Xia Zhan; Wenjun Ji; Xuefan Gu; Lianshu Han
Journal:  Front Genet       Date:  2022-02-15       Impact factor: 4.599

6.  Late-onset cblC deficiency around puberty: a retrospective study of the clinical characteristics, diagnosis, and treatment.

Authors:  Zhehui Chen; Hui Dong; Yao Zhang; Yanling Yang; Yupeng Liu; Ruxuan He; Jinqing Song; Ying Jin; Mengqiu Li; Yi Liu; Xueqin Liu; Hui Yan; Jianguang Qi; Fang Wang; Huijie Xiao; Hong Zheng; Lulu Kang; Dongxiao Li
Journal:  Orphanet J Rare Dis       Date:  2022-09-02       Impact factor: 4.303

Review 7.  Adult-onset CblC deficiency: a challenging diagnosis involving different adult clinical specialists.

Authors:  Silvia Kalantari; Brigida Brezzi; Valeria Bracciamà; Antonella Barreca; Paolo Nozza; Tiziana Vaisitti; Antonio Amoroso; Silvia Deaglio; Marco Manganaro; Francesco Porta; Marco Spada
Journal:  Orphanet J Rare Dis       Date:  2022-02-02       Impact factor: 4.123

8.  PRDX1 gene-related epi-cblC disease is a common type of inborn error of cobalamin metabolism with mono- or bi-allelic MMACHC epimutations.

Authors:  Catia Cavicchi; Abderrahim Oussalah; Silvia Falliano; Lorenzo Ferri; Alessia Gozzini; Serena Gasperini; Serena Motta; Miriam Rigoldi; Giancarlo Parenti; Albina Tummolo; Concetta Meli; Francesca Menni; Francesca Furlan; Marta Daniotti; Sabrina Malvagia; Giancarlo la Marca; Céline Chery; Pierre-Emmanuel Morange; David Tregouet; Maria Alice Donati; Renzo Guerrini; Jean-Louis Guéant; Amelia Morrone
Journal:  Clin Epigenetics       Date:  2021-07-02       Impact factor: 6.551

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.